Prostate Cancer News and Research

Latest Prostate Cancer News and Research

MHN forms Men's Health Caucus to improve health and well-being of men

Men's Health Network is pleased to announce the formation of a Men's Health Caucus in official relations with the American Public Health Association. As an active participant of the APHA Annual Meeting for many years we have seen growing interest and excitement generated around the need and desire to form a Men's Health Caucus and we are happy to see it come to fruition.

25 Feb 2010

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

Harbor BioSciences, Inc. today announced that the company has received a notice of allowance from the United States Patent Office of patent claims covering the use of its lead product candidate Apoptone®. The patent claims cover the use of Apoptone to treat prostate cancer, breast cancer and benign prostatic hypertrophy. Apoptone (HE3235) is a novel synthetic steroid analog of a dihydrotestosterone metabolite and has been found to stimulate cell death (apoptosis) in animal models of prostate and breast cancers.

25 Feb 2010

Gene expression in prostate cancer cell more complex than ever imagined

Scientists from Sydney's Garvan Institute of Medical Research have published a paper, online today in Nature Cell Biology, describing gene expression in a prostate cancer cell: more sweeping, more targeted and more complex than we could ever have imagined, even five years ago.

24 Feb 2010

New Barts Cancer Research UK Centre launched

A new cancer centre, launched today, puts London at the forefront of cancer research.

23 Feb 2010

Nation-wide study to assess risk of suicide among men

The introduction of prostate-specific antigen (PSA) testing as a screening tool for early detection of prostate cancer (PCa) in the beginning of the 1990s drastically increased the detection of PCa. The risk of suicide is increased among cancer patients including men with PCa.

23 Feb 2010

Smokers, tobacco users and high alcohol consumers: Get mouths, gums and tongues checked for cancer

The National Basketball Association's (NBA) Denver Nuggets Coach George Karl announced today that he has been diagnosed with treatable neck and throat cancer. According to published media reports, Karl's physician says the coach has cancer of his right tonsil that has spread to a lymph node in his neck. The 58-year-old Karl, who is also a prostate cancer survivor, coached in the NBA's All-Star game this past weekend.

22 Feb 2010

Study comparing open and laparoscopic radical prostatectomy reveals few differences in outcomes

Of the 200,000 men newly diagnosed with prostate cancer each year in the United States, about one-third will undergo surgical treatment. Although open radical prostatectomy (ORP) is regarded as the standard treatment, laparoscopic radical prostatectomy (LRP) with or without robotic assistance is becoming more common.

22 Feb 2010

Researchers develop new tool to understand how cancer grows

Researchers have a new tool to understand how cancers grow -- and with it a new opportunity to identify novel cancer drugs. They've been able to break apart human prostate tissue, extract the stem cells in that tissue, and alter those cells genetically so that they spur cancer.

22 Feb 2010

Amgen's Prolia Complete Response submission: FDA classifies and sets PDUFA date

Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has evaluated the content of the Company's Complete Response submission for Prolia™ (denosumab) in the treatment of postmenopausal osteoporosis and classified it as a Class 2 resubmission. With the Class 2 designation, the FDA set a corresponding Prescription Drug User Fee Act (PDUFA) action date of July 25, 2010.

20 Feb 2010

BioCrossroads' Indiana Seed Fund invests $400,000 in Bioscience Vaccines

BioCrossroads' Indiana Seed Fund has invested in Bioscience Vaccines, Inc. to accelerate the development of biologic materials, which may boost the effectiveness of a wide range of life-saving vaccines.

19 Feb 2010

11 cities to join DASH FOR DAD national race series to end prostate cancer

DASH FOR DAD, the premier prostate cancer race series in the U.S., is a heartfelt tight-knit community event that brings together athletes, cancer survivors, physicians, caregivers, family members and friends. Proceeds from each 10K race are used to provide free prostate cancer testing for men in the local community of the event.

19 Feb 2010

Roseville ROC commences cancer treatment with Elekta VMAT

The first treatments with Elekta Volumetric Modulated Arc Therapy (VMAT) began November 17, 2009 at Roseville Radiation Oncology Center (ROC) at Radiological Associates of Sacramento (RAS). RAS, a large private medical group, includes diagnostics as well as therapy in its centers. ROC treats 30-35 patients per day, mainly with prostate and breast lesions.

From Elekta 19 Feb 2010

Researcher develops acoustic resonant sensor that can test bodily fluids for variety of diseases

What if it were possible to go to the store and buy a kit to quickly and accurately diagnose cancer, similar to a pregnancy test? A University of Missouri researcher is developing a tiny sensor, known as an acoustic resonant sensor, that is smaller than a human hair and could test bodily fluids for a variety of diseases, including breast and prostate cancers.

18 Feb 2010

Researchers discover new prognosis marker for prostate cancer

Measuring levels of the active form of the protein EGFR in the tumor and its vicinity can provide a more reliable prognosis for individuals with prostate cancer.

18 Feb 2010

Soligenix' LPM oral drug delivery technology receives Hong Kong patent

Soligenix, Inc., a late-stage biotechnology company, announced today that it has received a Hong Kong patent which addresses its Lipid Polymer Micelle (LPM™) technology for the improved oral delivery of drugs. The issued Hong Kong patent, HK 1071054, entitled "Stabilized Reverse Micelle Compositions and Uses Thereof" covers lipid structures (reverse micelles) that promote the intestinal absorption of peptides and other sensitive drugs that cannot otherwise be given orally.

17 Feb 2010

Phase II clinical trial result of abiraterone drug shows promise for advanced prostate cancer

New results from a phase II clinical trial of the prostate cancer drug abiraterone suggest that it may help men with advanced disease who have tried standard treatments.

17 Feb 2010

Study: Earlier detection of lung cancer can reduce number of late stage lung cancer deaths

The first ever actuarial analysis of lung cancer mortality, published today in Population Health Management Journal, provides strong evidence that earlier detection could reduce the number of late stage lung cancer deaths by over 70,000 people each year in the US.

17 Feb 2010

Calypso real-time tumor tracking system usage during IMRT for prostate cancer reduces rectal/urinary side effects

Calypso Medical Technologies, Inc., a developer of targeting technology used for accurate, precise real-time tracking of tumor targets, today announced the online publication of a clinical study in Urology (The GOLD JOURNAL). The prospective, multi-site study, entitled, “Assessing the Impact of Margin Reduction (AIM),” is the first outcomes-based study to evaluate the quality of life of high-dose intensity-modulated radiotherapy (IMRT) to the prostate with tightly contoured treatment technically described as “reduced treatment margins.”

17 Feb 2010

New fluorescent probes improve tumor detection in mice

Building on his Nobel Prize-winning work creating fluorescent proteins that light up the inner workings of cells, a team of researchers led by Howard Hughes Medical Institute investigator Roger Tsien, PhD, professor of pharmacology, chemistry and biochemistry at the University of California, San Diego and the Moores UCSD Cancer Center has developed biological probes that can stick to and light up tumors in mice.

17 Feb 2010

CNRS-Institut researchers identify 'virulence factor' that inhibits host immune response

Oncogenic retroviruses are a particular family of viruses that can cause some types of cancer. Thierry Heidmann and his colleagues in the CNRS-Institut Gustave Roussy-Université Paris Sud 11 "Rétrovirus endogènes et éléments rétroïdes des eucaryotes supérieurs" Laboratory have studied these viruses. They have identified a "virulence factor" that inhibits the host immune response and allows the virus to spread throughout the body.

16 Feb 2010

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

MHN forms Men's Health Caucus to improve health and well-being of men

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

Gene expression in prostate cancer cell more complex than ever imagined

New Barts Cancer Research UK Centre launched

Nation-wide study to assess risk of suicide among men

Smokers, tobacco users and high alcohol consumers: Get mouths, gums and tongues checked for cancer

Study comparing open and laparoscopic radical prostatectomy reveals few differences in outcomes

Researchers develop new tool to understand how cancer grows

Amgen's Prolia Complete Response submission: FDA classifies and sets PDUFA date

BioCrossroads' Indiana Seed Fund invests $400,000 in Bioscience Vaccines

11 cities to join DASH FOR DAD national race series to end prostate cancer

Roseville ROC commences cancer treatment with Elekta VMAT

Researcher develops acoustic resonant sensor that can test bodily fluids for variety of diseases

Researchers discover new prognosis marker for prostate cancer

Soligenix' LPM oral drug delivery technology receives Hong Kong patent

Phase II clinical trial result of abiraterone drug shows promise for advanced prostate cancer

Study: Earlier detection of lung cancer can reduce number of late stage lung cancer deaths

Calypso real-time tumor tracking system usage during IMRT for prostate cancer reduces rectal/urinary side effects

New fluorescent probes improve tumor detection in mice

CNRS-Institut researchers identify 'virulence factor' that inhibits host immune response

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in